BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 23071347)

  • 1. The impact of acquisition time on image quality in whole-body 18F-FDG PET/CT for cancer staging.
    Hausmann D; Dinter DJ; Sadick M; Brade J; Schoenberg SO; Büsing K
    J Nucl Med Technol; 2012 Dec; 40(4):255-8. PubMed ID: 23071347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of acquisition time on visual and semi-quantitative analysis of F-18 FDG-PET studies in patients with head and neck cancer.
    Goethals I; D'Asseler Y; Dobbeleir A; Deblaere K; Ham H
    Nucl Med Commun; 2010 Mar; 31(3):227-31. PubMed ID: 20023593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system.
    Schmidt H; Brendle C; Schraml C; Martirosian P; Bezrukov I; Hetzel J; Müller M; Sauter A; Claussen CD; Pfannenberg C; Schwenzer NF
    Invest Radiol; 2013 May; 48(5):247-55. PubMed ID: 23519008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of the optimal acquisition protocol of breath-hold PET/CT for the diagnosis of thoracic lesions.
    Mitsumoto K; Abe K; Sakaguchi Y; Zhang T; Tachiya Y; Ohya N; Baba S; Sasaki M
    Nucl Med Commun; 2011 Dec; 32(12):1148-54. PubMed ID: 21968434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical impact of "true whole-body" (18)F-FDG PET/CT: lesion frequency and added benefit in distal lower extremities.
    Kawata S; Imaizumi M; Kako Y; Oku N
    Ann Nucl Med; 2014 May; 28(4):322-8. PubMed ID: 24488705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Performance of whole-body integrated 18F-FDG PET/MR in comparison to PET/CT for evaluation of malignant bone lesions.
    Eiber M; Takei T; Souvatzoglou M; Mayerhoefer ME; Fürst S; Gaertner FC; Loeffelbein DJ; Rummeny EJ; Ziegler SI; Schwaiger M; Beer AJ
    J Nucl Med; 2014 Feb; 55(2):191-7. PubMed ID: 24309383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrated whole-body PET/MR hybrid imaging: clinical experience.
    Quick HH; von Gall C; Zeilinger M; Wiesmüller M; Braun H; Ziegler S; Kuwert T; Uder M; Dörfler A; Kalender WA; Lell M
    Invest Radiol; 2013 May; 48(5):280-9. PubMed ID: 23442775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of patient weight and emission scan duration on PET/CT image quality and lesion detectability.
    Halpern BS; Dahlbom M; Quon A; Schiepers C; Waldherr C; Silverman DH; Ratib O; Czernin J
    J Nucl Med; 2004 May; 45(5):797-801. PubMed ID: 15136629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving the detection of small lesions using a state-of-the-art time-of-flight PET/CT system and small-voxel reconstructions.
    Koopman D; van Dalen JA; Lagerweij MC; Arkies H; de Boer J; Oostdijk AH; Slump CH; Jager PL
    J Nucl Med Technol; 2015 Mar; 43(1):21-7. PubMed ID: 25613334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing positron emission tomography image acquisition protocols in integrated positron emission tomography/magnetic resonance imaging.
    Hartung-Knemeyer V; Beiderwellen KJ; Buchbender C; Kuehl H; Lauenstein TC; Bockisch A; Poeppel TD
    Invest Radiol; 2013 May; 48(5):290-4. PubMed ID: 23399811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Qualitative and quantitative comparison of PET/CT and PET/MR imaging in clinical practice.
    Al-Nabhani KZ; Syed R; Michopoulou S; Alkalbani J; Afaq A; Panagiotidis E; O'Meara C; Groves A; Ell P; Bomanji J
    J Nucl Med; 2014 Jan; 55(1):88-94. PubMed ID: 24337608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal dose of 18F-FDG required for whole-body PET using an LSO PET camera.
    Everaert H; Vanhove C; Lahoutte T; Muylle K; Caveliers V; Bossuyt A; Franken PR
    Eur J Nucl Med Mol Imaging; 2003 Dec; 30(12):1615-9. PubMed ID: 14504831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of whole-body PET/CT and PET/MRI in breast cancer patients: lesion detection and quantitation of 18F-deoxyglucose uptake in lesions and in normal organ tissues.
    Pace L; Nicolai E; Luongo A; Aiello M; Catalano OA; Soricelli A; Salvatore M
    Eur J Radiol; 2014 Feb; 83(2):289-96. PubMed ID: 24331845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of 18F-fluoride PET/MR and PET/CT in patients with foot pain of unclear cause.
    Rauscher I; Beer AJ; Schaeffeler C; Souvatzoglou M; Crönlein M; Kirchhoff C; Sandmann G; Fürst S; Kilger R; Herz M; Ziegler S; Schwaiger M; Eiber M
    J Nucl Med; 2015 Mar; 56(3):430-5. PubMed ID: 25678485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, double-blind, crossover comparison of novel continuous bed motion versus traditional bed position whole-body PET/CT imaging.
    Schatka I; Weiberg D; Reichelt S; Owsianski-Hille N; Derlin T; Berding G; Bengel FM
    Eur J Nucl Med Mol Imaging; 2016 Apr; 43(4):711-7. PubMed ID: 26546010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low positive yield from routine inclusion of the brain in whole-body 18F-FDG PET/CT imaging for noncerebral malignancies: results from a large population study.
    Manohar K; Bhattacharya A; Mittal BR
    Nucl Med Commun; 2013 Jun; 34(6):540-3. PubMed ID: 23503001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of integrated whole-body PET/MR and PET/CT: Is PET/MR alternative to PET/CT in routine clinical oncology?
    Ishii S; Shimao D; Hara T; Miyajima M; Kikuchi K; Takawa M; Kumamoto K; Ito H; Shishido F
    Ann Nucl Med; 2016 Apr; 30(3):225-33. PubMed ID: 26676720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and therapeutic impact of 18F-FDG PET/CT whole-body acquisition including lower limbs in patients with malignant melanoma.
    Querellou S; Keromnes N; Abgral R; Sassolas B; Le Roux PY; Cavarec MB; Le Duc-Pennec A; Couturier O; Salaun PY
    Nucl Med Commun; 2010 Sep; 31(9):766-72. PubMed ID: 20585271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Focal fluorine-18 fluorodeoxyglucose-avid lesions without computed tomography correlate at whole-body positron emission tomography-computed tomography in oncology patients: how often are they malignant?
    Kumar R; Hawkins RA; Yeh BM; Wang ZJ
    Nucl Med Commun; 2011 Sep; 32(9):802-7. PubMed ID: 21685821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.